MesaGreen Pharmaceutical Company Files Investigational New Animal Drug Application

The application covers the development of the company’s K9MGP product which, when approved, will effectively control an active seizure in dogs for use by pet owners in the home.

FREDERICK, Md. (PRWEB) November 11, 2022

MesaGreen Pharmaceutical Company today announced that it has filed an Investigational New Animal Drug (INAD) application with the Food and Drug Administration (FDA). INAD covers the development of the company’s K9MGP product which, when approved, will effectively control an active seizure in dogs for use by pet owners in the home.

Seizures can have serious effects on the brain and can be a medical emergency. Pet owners often experience significant emotional stress during their dog’s seizure, and treatment can be a financial burden. Currently, there are no FDA-approved medications indicated to control active seizures in dogs.

Mr. Michael Mesa, CEO and President of MesaGreen Pharmaceutical Company states “Currently, dog owners have limited choices when faced with a seizure animal in the home and with millions of dogs suffering from seizures each year, there are a significant unmet medical need that we intend to fill with K9MGP.”

Michael Podell DMV. MSC, DACVIM (Neurology), Scientific Advisor to MesaGreen Pharmaceutical Company, added: “The most important thing a veterinarian can provide to an owner living with an epileptic dog is the ability to feel confident that they can handle an epileptic fit at home. this opportunity to provide safe and effective in-home lifesaving therapy will meet the criteria to not only improve the lives of affected dogs, but also those of their owners by providing the security of knowing that they can provide meaningful help.”

Studies conducted under INAD will provide dosing, safety and efficacy data that will support a New Animal Drug Application (NADA) for marketing approval of K9MGP.

MesaGreen Pharmaceutical Company is a small, veteran-owned company and is a subsidiary of Mesa Science Associates, Inc. Both companies are located inside the Frederick Innovation and Technology Center on Metropolitan Court in Frederick MD.

For the original version on PRWeb, visit: https://www.prweb.com/releases/mesagreen_pharmaceutical_company_files_an_investigational_new_animal_drug_application/prweb19015657.htm